Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the IfInhibitor Ivabradine Trial (SHIFT)

Karl Swedberg; Michel Komajda; Michael Böhm; Jeffrey S. Borer; Ian Ford; Luigi Tavazzi

doi:10.1093/eurjhf/hfp154

Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the IfInhibitor Ivabradine Trial (SHIFT)

European Journal of Heart Failure ◽

10.1093/eurjhf/hfp154 ◽

2009 ◽

Vol 12 (1) ◽

pp. 75-81 ◽

Cited By ~ 71

Author(s):

Karl Swedberg ◽

Michel Komajda ◽

Michael Böhm ◽

Jeffrey S. Borer ◽

Ian Ford ◽

...

Keyword(s):

Heart Failure ◽

Chronic Heart Failure ◽

Systolic Heart Failure ◽

Double Blind ◽

Heart Failure Treatment ◽

Double Blind Placebo ◽

Failure Treatment ◽

Outcome Trial

Download Full-text

Faculty Opinions recommendation of Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717297963.792752819 ◽

2012 ◽

Author(s):

David Taylor ◽

Ethan Anderson

Keyword(s):

Heart Failure ◽

Fatty Acids ◽

Chronic Heart Failure ◽

Left Ventricular ◽

Omega 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Systolic Left Ventricular Function ◽

Markers Of Inflammation ◽

Dose Dependent

Download Full-text

The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial

The Lancet ◽

10.1016/s0140-6736(11)61126-4 ◽

2011 ◽

Vol 378 (9792) ◽

pp. 676-683 ◽

Cited By ~ 216

Author(s):

John GF Cleland ◽

John R Teerlink ◽

Roxy Senior ◽

Evgeny M Nifontov ◽

John JV Mc Murray ◽

...

Keyword(s):

Heart Failure ◽

Cardiac Function ◽

Systolic Heart Failure ◽

Phase 2 ◽

Cardiac Myosin ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Trial ◽

Omecamtiv Mecarbil ◽

Dose Ranging

Download Full-text

Heart Rate Control With If Inhibitor, Ivabradine, in Japanese Patients With Chronic Heart Failure　– A Randomized, Double-Blind, Placebo-Controlled Phase II Study –

Circulation Journal ◽

10.1253/circj.cj-15-1112 ◽

2016 ◽

Vol 80 (3) ◽

pp. 668-676 ◽

Cited By ~ 18

Author(s):

Hiroyuki Tsutsui ◽

Shinichi Momomura ◽

Akira Yamashina ◽

Hisao Ogawa ◽

Hiroaki Shimokawa ◽

...

Keyword(s):

Heart Failure ◽

Heart Rate ◽

Chronic Heart Failure ◽

Phase Ii ◽

Rate Control ◽

Phase Ii Study ◽

Japanese Patients ◽

Heart Rate Control ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure

Journal of the American College of Cardiology ◽

10.1016/0735-1097(93)90816-j ◽

1993 ◽

Vol 22 (1) ◽

pp. 65-72 ◽

Cited By ~ 92

Author(s):

Milton Packer ◽

◽

Kenneth A. Narahara ◽

Uri Elkayam ◽

Jay M. Sullivan ◽

...

Keyword(s):

Heart Failure ◽

Chronic Heart Failure ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Rationale and design of the DIGIT‐HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double‐blind, placebo‐controlled study

European Journal of Heart Failure ◽

10.1002/ejhf.1452 ◽

2019 ◽

Vol 21 (5) ◽

pp. 676-684 ◽

Cited By ~ 10

Author(s):

Udo Bavendiek ◽

Dominik Berliner ◽

Lukas Aguirre Dávila ◽

Johannes Schwab ◽

Lars Maier ◽

...

Keyword(s):

Heart Failure ◽

Chronic Heart Failure ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A randomised, double‐blind, placebo‐controlled trial of metformin on myocardial efficiency in insulin‐resistant chronic heart failure patients without diabetes

European Journal of Heart Failure ◽

10.1002/ejhf.1656 ◽

2019 ◽

Vol 22 (9) ◽

pp. 1628-1637 ◽

Cited By ~ 8

Author(s):

Anders Hostrup Larsen ◽

Niels Jessen ◽

Helene Nørrelund ◽

Lars Poulsen Tolbod ◽

Hendrik Johannes Harms ◽

...

Keyword(s):

Heart Failure ◽

Chronic Heart Failure ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Heart Failure Patients ◽

Insulin Resistant ◽

Myocardial Efficiency

Download Full-text

The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT)

American Heart Journal ◽

10.1016/j.ahj.2020.09.020 ◽

2021 ◽

Vol 231 ◽

pp. 137-146

Author(s):

Henrik Wiggers ◽

Lars Køber ◽

Gunnar Gislason ◽

Morten Schou ◽

Mikael Kjær Poulsen ◽

...

Keyword(s):

Heart Failure ◽

Chronic Heart Failure ◽

Isosorbide Dinitrate ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Factorial Trial

Download Full-text

Clinical consequences of angiotensin-converting enzyme inhibitor withdrawl in chronic heart failure: A double-blind, placebo-controlled study of quinapril

Journal of the American College of Cardiology ◽

10.1016/0735-1097(93)90578-o ◽

1993 ◽

Vol 22 (6) ◽

pp. 1557-1563 ◽

Cited By ~ 59

Author(s):

Peter W. Pflugfelder ◽

G. Baird ◽

Melvin J. Tonkon ◽

Robert DiBianco ◽

Bertram Pitt

Keyword(s):

Heart Failure ◽

Chronic Heart Failure ◽

Angiotensin Converting Enzyme ◽

Angiotensin Converting Enzyme Inhibitor ◽

Enzyme Inhibitor ◽

Controlled Study ◽

Converting Enzyme ◽

Double Blind ◽

Double Blind Placebo ◽

Clinical Consequences

Download Full-text

Results of a twelve week double-blind, placebo-controlled, multicenter study of oral conivaptan to assess functional capacity in patients with class III chronic heart failure

Journal of Cardiac Failure ◽

10.1016/s1071-9164(03)00528-1 ◽

2003 ◽

Vol 9 (5) ◽

pp. S60 ◽

Cited By ~ 10

Author(s):

Stuart D. Russell ◽

Kirkwood F. Adams ◽

James P. Shaw ◽

Wendy A. Gattis ◽

Christopher M. O'Connor

Keyword(s):

Heart Failure ◽

Chronic Heart Failure ◽

Functional Capacity ◽

Multicenter Study ◽

Class Iii ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Effects of Lixivaptan, a Novel Vasopressin V2 Receptor Antagonist, in Chronic Heart Failure: Results from a Double-Blind, Placebo-Controlled, Multiple-Dose Study

Journal of Cardiac Failure ◽

10.1016/j.cardfail.2008.06.193 ◽

2008 ◽

Vol 14 (6) ◽

pp. S71

Author(s):

William Abraham ◽

Steven Goldsmith ◽

Stephen Gottlieb

Keyword(s):

Heart Failure ◽

Chronic Heart Failure ◽

Multiple Dose ◽

Double Blind ◽

Double Blind Placebo ◽

Multiple Dose Study ◽

Dose Study ◽

V2 Receptor ◽

Vasopressin V2 Receptor Antagonist ◽

V2 Receptor Antagonist

Download Full-text

Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the IfInhibitor Ivabradine Trial (SHIFT)

Faculty Opinions recommendation of Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study.

The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial

Heart Rate Control With If Inhibitor, Ivabradine, in Japanese Patients With Chronic Heart Failure – A Randomized, Double-Blind, Placebo-Controlled Phase II Study –

Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure

Rationale and design of the DIGIT‐HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double‐blind, placebo‐controlled study

A randomised, double‐blind, placebo‐controlled trial of metformin on myocardial efficiency in insulin‐resistant chronic heart failure patients without diabetes

Clinical consequences of angiotensin-converting enzyme inhibitor withdrawl in chronic heart failure: A double-blind, placebo-controlled study of quinapril

Results of a twelve week double-blind, placebo-controlled, multicenter study of oral conivaptan to assess functional capacity in patients with class III chronic heart failure

Effects of Lixivaptan, a Novel Vasopressin V2 Receptor Antagonist, in Chronic Heart Failure: Results from a Double-Blind, Placebo-Controlled, Multiple-Dose Study

Heart Rate Control With If Inhibitor, Ivabradine, in Japanese Patients With Chronic Heart Failure　– A Randomized, Double-Blind, Placebo-Controlled Phase II Study –